• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吉非替尼诱发的转移性肺腺癌皮肤溃疡

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung.

作者信息

Sathyanarayanan Vishwanath, Lokesh Kadabur Nagendrappa, Channaviriappa Lakshmaiah Kuntejowdahalli, Jacob Linu Abraham

机构信息

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.

出版信息

Indian J Med Paediatr Oncol. 2014 Jan;35(1):109-10. doi: 10.4103/0971-5851.133736.

DOI:10.4103/0971-5851.133736
PMID:25006299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4080647/
Abstract

We report a case of gefitinib-induced skin ulceration in a 50-year-old female with metastatic adenocarcinoma of lung who developed this adverse effect 2 weeks following initiation of gefitinib at a dose of 250 mg/day. The ulcer improved with stopping gefitinib for 2 weeks and also addition of topical steroids and antibiotics. We are reporting this case to create awareness among treating oncologists of this adverse effect and also prompt interruption of therapy and topical steroids/antibiotics is useful to treat this adverse event.

摘要

我们报告一例50岁女性肺转移性腺癌患者,在开始每日服用250毫克吉非替尼2周后出现吉非替尼诱发的皮肤溃疡。停用吉非替尼2周,并加用外用类固醇和抗生素后,溃疡有所改善。我们报告此病例是为了提高肿瘤治疗医生对这种不良反应的认识,同时提示治疗中断以及外用类固醇/抗生素对治疗这一不良事件是有用的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9dd/4080647/ec6abb9cdf49/IJMPO-35-109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9dd/4080647/ec6abb9cdf49/IJMPO-35-109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9dd/4080647/ec6abb9cdf49/IJMPO-35-109-g001.jpg

相似文献

1
Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung.吉非替尼诱发的转移性肺腺癌皮肤溃疡
Indian J Med Paediatr Oncol. 2014 Jan;35(1):109-10. doi: 10.4103/0971-5851.133736.
2
Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report.吉非替尼治疗肺转移性腺癌患者的角膜穿孔性溃疡:一例报告
Case Rep Ophthalmol Med. 2012;2012:379132. doi: 10.1155/2012/379132. Epub 2012 Dec 18.
3
Ocular Adverse Effects of Gefitinib: A Case Report.吉非替尼的眼部不良反应:一例报告
Cureus. 2022 Sep 26;14(9):e29600. doi: 10.7759/cureus.29600. eCollection 2022 Sep.
4
Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature.吉非替尼治疗晚期肺癌患者的非典型皮肤反应:一例报告并文献复习
Exp Ther Med. 2016 Jan;11(1):197-200. doi: 10.3892/etm.2015.2881. Epub 2015 Nov 19.
5
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib.吉非替尼治疗的肺腺癌患者双侧严重角膜溃疡
Case Rep Ophthalmol. 2021 Apr 30;12(1):288-292. doi: 10.1159/000514696. eCollection 2021 Jan-Apr.
6
Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.吉非替尼表皮生长因子受体靶向治疗局部晚期和转移性原发性肺腺癌。
Respirology. 2006 May;11(3):287-91. doi: 10.1111/j.1440-1843.2006.00840.x.
7
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.在接受吉非替尼治疗既往治疗过的晚期或转移性非小细胞肺癌患者中,皮疹和支气管肺泡组织学与临床获益相关。
Lung Cancer. 2006 Jan;51(1):89-96. doi: 10.1016/j.lungcan.2005.09.002. Epub 2005 Nov 14.
8
Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients.在日本患者中,吉非替尼引起的皮疹是晚期肺腺癌患者预后良好的一个迹象。
Springerplus. 2013 Dec;2(1):22. doi: 10.1186/2193-1801-2-22. Epub 2013 Jan 23.
9
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
10
Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report.吉非替尼再治疗对一名具有鳞屑为主型腺癌的肺癌患者产生显著效果,该患者初始使用吉非替尼治疗取得良好疗效:一例报告
J Clin Med Res. 2012 Jun;4(3):216-20. doi: 10.4021/jocmr816e. Epub 2012 May 15.

引用本文的文献

1
Amivantamab, the first epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia.阿米万他单抗是首个表皮生长因子受体和间充质上皮转化因子抑制剂,与阴茎及腹股沟溃疡和甲沟炎有关。
JAAD Case Rep. 2024 Jan 27;45:113-116. doi: 10.1016/j.jdcr.2024.01.014. eCollection 2024 Mar.

本文引用的文献

1
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者(WJTOG3405):一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
2
Treatment of gefitinib-associated folliculitis.吉非替尼相关性毛囊炎的治疗。
J Am Acad Dermatol. 2006 Oct;55(4):710-3. doi: 10.1016/j.jaad.2006.06.034.
3
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
Br J Dermatol. 2004 Jul;151(1):238-41. doi: 10.1111/j.1365-2133.2004.06026.x.
4
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Acta Derm Venereol. 2004;84(1):23-6. doi: 10.1080/00015550310005898.
5
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.美国食品药品监督管理局药品批准摘要:吉非替尼(ZD1839;易瑞沙)片。
Clin Cancer Res. 2004 Feb 15;10(4):1212-8. doi: 10.1158/1078-0432.ccr-03-0564.
6
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.表皮生长因子受体抑制剂ZD1839在癌症患者皮肤中的药效学研究:受体抑制的组织病理学和分子学后果
J Clin Oncol. 2002 Jan 1;20(1):110-24. doi: 10.1200/JCO.2002.20.1.110.